| pubmed-article:10540953 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10540953 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:10540953 | lifeskim:mentions | umls-concept:C0000854 | lld:lifeskim |
| pubmed-article:10540953 | lifeskim:mentions | umls-concept:C0022322 | lld:lifeskim |
| pubmed-article:10540953 | lifeskim:mentions | umls-concept:C0042523 | lld:lifeskim |
| pubmed-article:10540953 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:10540953 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:10540953 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:10540953 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:10540953 | pubmed:dateCreated | 2000-1-20 | lld:pubmed |
| pubmed-article:10540953 | pubmed:abstractText | The effect of verapamil, a multidrug-resistance (Mdr)-reversing agent on the absorption of a pour-on formulation of ivermectin was evaluated in rats. Absorption of ivermectin was effectively enhanced (40%) by the presence of verapamil, suggesting that absorption of ivermectin involves Mdr-P-glycoprotein and that verapamil should act as a competitive inhibitor for the transport and extrusion of ivermectin by P-glycoprotein. This hypothesis is consistent with other studies describing verapamil as a blocking agent of P-glycoprotein involved in the efflux of ivermectin in a resistant strain of Haemonchus contortus. | lld:pubmed |
| pubmed-article:10540953 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10540953 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10540953 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10540953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10540953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10540953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10540953 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10540953 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:10540953 | pubmed:issn | 0932-0113 | lld:pubmed |
| pubmed-article:10540953 | pubmed:author | pubmed-author:AlvinerieMM | lld:pubmed |
| pubmed-article:10540953 | pubmed:author | pubmed-author:EeckhoutteCC | lld:pubmed |
| pubmed-article:10540953 | pubmed:author | pubmed-author:SutraJ FJF | lld:pubmed |
| pubmed-article:10540953 | pubmed:author | pubmed-author:DupuyJJ | lld:pubmed |
| pubmed-article:10540953 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10540953 | pubmed:volume | 85 | lld:pubmed |
| pubmed-article:10540953 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10540953 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10540953 | pubmed:pagination | 920-2 | lld:pubmed |
| pubmed-article:10540953 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:meshHeading | pubmed-meshheading:10540953... | lld:pubmed |
| pubmed-article:10540953 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10540953 | pubmed:articleTitle | Enhanced absorption of pour-on ivermectin formulation in rats by co-administration of the multidrug-resistant-reversing agent verapamil. | lld:pubmed |
| pubmed-article:10540953 | pubmed:affiliation | Laboratoire de Pharmacologie-Toxicologie, INRA, Toulouse, France. malviner@toulouse.inra.fr | lld:pubmed |
| pubmed-article:10540953 | pubmed:publicationType | Journal Article | lld:pubmed |
